Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01) : Annals of Surgery

Journal Logo

You can read the full text of this article if you:

Access through Ovid
RANDOMIZED CONTROLLED TRIAL

Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01)

Yamaguchi, Junpei MD; Yokoyama, Yukihiro MD; Fujii, Tsutomu MD||; Yamada, Suguru MD; Takami, Hideki MD; Kawashima, Hiroki MD; Ohno, Eizaburo MD; Ishikawa, Takuya MD; Maeda, Osamu MD§; Ogawa, Hiroshi MD; Kodera, Yasuhiro MD; Nagino, Masato MD; Ebata, Tomoki MD

Author Information
doi: 10.1097/SLA.0000000000005430
  • Buy
  • SDC

Abstract

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.